Merck's Gardasil generated $1 billion in Q3, prompting an analyst to wonder just how much the shot might be able to generate in the long run.
Johnson & Johnson has big ambitions in vaccines, and to get there, its manufacturing capacity has to measure up.
Here is some other vaccine news of note for the week.
An initial analysis showed that J&J's four-strain HIV vaccine elicited a broader immune response than an older trivalent version.
While Seqirus works to boost manufacturing for its cell-based flu vaccine in the U.S., the shot is nearing an approval in Europe.
If the German contract manufacturer delivers all projects over the 10-year course, it could receive up to $80 million.
Seqirus says it is phasing delivery of its flu vaccine Fluad to the U.K. ahead of the peak season, though pharmacists have reported a lack of supply.
The punishment, an amount rarely seen in China, includes confiscation of illegal gains and a fine three times those sales.
For the third year in a row, the percentage of U.S. kindergarteners with a vaccine exemption has grown, this time to 2.2%.